Aurinia Pharmaceuticals Inc. (AUPH) Earnings History
Annual and quarterly earnings data from 1998 to 2025
Loading earnings history...
AUPH EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AUPH Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 88.5% | 37.1% | 101.5% |
| 2024 | 88.0% | -2.0% | 2.4% |
| 2023 | 91.9% | -52.2% | -44.5% |
| 2022 | 95.8% | -83.2% | -80.7% |
| 2021 | 97.6% | -396.3% | -396.8% |
Download Data
Export AUPH earnings history in CSV or JSON format
Free sign-in required to download data
Aurinia Pharmaceuticals Inc. (AUPH) Earnings Overview
As of May 6, 2026, Aurinia Pharmaceuticals Inc. (AUPH) reported trailing twelve-month net income of $287M, reflecting +5167.2% year-over-year growth. The company earned $2.07 per diluted share over the past four quarters, with a net profit margin of 101.5%.
Looking at the long-term picture, AUPH's historical earnings data spans multiple years. The company achieved its highest annual net income of $287M in fiscal 2025, representing a new all-time high.
Aurinia Pharmaceuticals Inc. maintains industry-leading profitability with a gross margin of 88.5%, operating margin of 37.1%, and net margin of 101.5%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including LGND ($49M net income, -2.4% margin), ANIP ($78M net income, 8.9% margin), PRAX (-$303M net income), AUPH has outperformed on profitability metrics. Compare AUPH vs LGND →
AUPH Earnings vs Peers
Earnings metrics vs comparable public companies
AUPH Historical Earnings Data (1998–2025)
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $287M | +4893.1% | $105M | $2.07 | 101.5% | 37.1% |
| 2024 | $6M | +107.4% | -$5M | $0.04 | 2.4% | -2.0% |
| 2023 | -$78M | +27.9% | -$92M | $-0.54 | -44.5% | -52.2% |
| 2022 | -$108M | +40.2% | -$111M | $-0.76 | -80.7% | -83.2% |
| 2021 | -$181M | -76.2% | -$181M | $-1.40 | -396.8% | -396.3% |
| 2020 | -$103M | -16.2% | -$104M | $-0.87 | -204.9% | -208.1% |
| 2019 | -$88M | -37.8% | -$91M | $-1.33 | -27794.0% | -28598.4% |
| 2018 | -$64M | +9.4% | -$56M | $-0.76 | -13848.8% | -12129.2% |
| 2017 | -$71M | -203.9% | -$47M | $-0.92 | -16855.2% | -11205.5% |
| 2016 | -$23M | -25.2% | -$23M | $-0.66 | -13465.3% | -13187.3% |
See AUPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AUPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AUPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAUPH — Frequently Asked Questions
Quick answers to the most common questions about buying AUPH stock.
Is AUPH growing earnings?
AUPH EPS is $2.07, with earnings growth accelerating to +5167.2%. This exceeds the 5-year CAGR of N/A. TTM net income reached $287M.
What are AUPH's profit margins?
Aurinia Pharmaceuticals Inc. net margin is +101.5%, with operating margin at +37.1%. Above-average margins indicate pricing power.
How consistent are AUPH's earnings?
AUPH earnings data spans 1998-2025. The accelerating earnings trend is +5167.2% YoY. Historical data enables comparison across business cycles.